[Immunosuppresive therapy of progredient chronic polyarthritis using antimetabolites and cytostatics].
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D000937:Antigen-Antibody Reactions; D000963:Antimetabolites / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001379:Azathioprine / Q000627:therapeutic use; D001799:Blood Sedimentation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007269:Injections, Intra-Arterial; D007958:Leukocyte Count; D008727:Methotrexate / Q000627:therapeutic use; D011687:Purines / Q000037:antagonists & inhibitors; D012217:Rheumatoid Factor; D013852:Thiotepa / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000963:Antimetabolites; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D011687:Purines; D012217:Rheumatoid Factor; D013852:Thiotepa; D001379:Azathioprine; D008727:Methotrexate
Die immunsuppressive Behandlung der progredient chronischen Polyarthritis mit Antimetabolica und Cytostatica.